Phase II clinical trial - Recherches "plusieurs pathologies"

This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of nivolumab monotherapy in 5 cohorts of patients with specific rare cancers who have unresectable locally advanced or metastatic disease, which is resistant or refractory to standard therapy, or for which standard therapy does not exist, or is not considered appropriate, and for which no other experimental treatment options are available.;Rare cancers eligible : ;1) rare head and neck cancers;2) rare skin cancers;3) rare kidney cancers;4) penile cancer;5) cancers harbouring a POLE E mutation